ATHA
Price
$0.38
Change
-$0.01 (-2.56%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
15.33M
65 days until earnings call
DYN
Price
$13.49
Change
-$0.00 (-0.00%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
1.92B
58 days until earnings call
Interact to see
Advertisement

ATHA vs DYN

Header iconATHA vs DYN Comparison
Open Charts ATHA vs DYNBanner chart's image
Athira Pharma
Price$0.38
Change-$0.01 (-2.56%)
Volume$725
Capitalization15.33M
Dyne Therapeutics
Price$13.49
Change-$0.00 (-0.00%)
Volume$51.85K
Capitalization1.92B
ATHA vs DYN Comparison Chart in %
Loading...
ATHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHA vs. DYN commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHA is a Hold and DYN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ATHA: $0.39 vs. DYN: $13.49)
Brand notoriety: ATHA and DYN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHA: 29% vs. DYN: 63%
Market capitalization -- ATHA: $15.33M vs. DYN: $1.92B
ATHA [@Biotechnology] is valued at $15.33M. DYN’s [@Biotechnology] market capitalization is $1.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHA’s FA Score shows that 1 FA rating(s) are green whileDYN’s FA Score has 1 green FA rating(s).

  • ATHA’s FA Score: 1 green, 4 red.
  • DYN’s FA Score: 1 green, 4 red.
According to our system of comparison, DYN is a better buy in the long-term than ATHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATHA’s TA Score shows that 2 TA indicator(s) are bullish while DYN’s TA Score has 4 bullish TA indicator(s).

  • ATHA’s TA Score: 2 bullish, 4 bearish.
  • DYN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DYN is a better buy in the short-term than ATHA.

Price Growth

ATHA (@Biotechnology) experienced а -2.36% price change this week, while DYN (@Biotechnology) price change was +7.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

ATHA is expected to report earnings on Nov 06, 2025.

DYN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYN($1.92B) has a higher market cap than ATHA($15.3M). ATHA YTD gains are higher at: -33.765 vs. DYN (-42.742). ATHA has higher annual earnings (EBITDA): -56.92M vs. DYN (-437.37M). DYN has more cash in the bank: 684M vs. ATHA (29.8M). ATHA has less debt than DYN: ATHA (1.02M) vs DYN (121M). ATHA (0) and DYN (0) have equivalent revenues.
ATHADYNATHA / DYN
Capitalization15.3M1.92B1%
EBITDA-56.92M-437.37M13%
Gain YTD-33.765-42.74279%
P/E RatioN/AN/A-
Revenue00-
Total Cash29.8M684M4%
Total Debt1.02M121M1%
TECHNICAL ANALYSIS
Technical Analysis
ATHADYN
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
88%
Momentum
ODDS (%)
Bearish Trend 5 days ago
83%
N/A
MACD
ODDS (%)
Bearish Trend 5 days ago
81%
N/A
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
85%
Bullish Trend 5 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 14 days ago
89%
BollingerBands
ODDS (%)
N/A
Bearish Trend 5 days ago
78%
Aroon
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GFVCX15.77-0.01
-0.06%
Goldman Sachs Focused Value C
HFYSX12.93-0.04
-0.31%
Hartford Schroders Intl Multi-Cp Val R4
FMCLX16.16-0.09
-0.55%
Federated Hermes Mid-Cap Index R6
AGWRX55.62-0.67
-1.19%
American Century Growth R
NWCCX43.57-0.61
-1.38%
Nuveen Winslow Large-Cap Growth ESG C

ATHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHA has been loosely correlated with CSCI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHA jumps, then CSCI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHA
1D Price
Change %
ATHA100%
-1.74%
CSCI - ATHA
42%
Loosely correlated
-3.99%
DYN - ATHA
37%
Loosely correlated
-1.89%
OGEN - ATHA
35%
Loosely correlated
-7.90%
MNKD - ATHA
33%
Poorly correlated
+2.23%
PBM - ATHA
32%
Poorly correlated
-5.39%
More

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
-1.89%
RNA - DYN
58%
Loosely correlated
-4.12%
CRNX - DYN
54%
Loosely correlated
+1.11%
SYRE - DYN
52%
Loosely correlated
-1.38%
XNCR - DYN
52%
Loosely correlated
+0.99%
IDYA - DYN
50%
Loosely correlated
-1.52%
More